



ARSEUS

Driving superior care

Press Release

Regulated information

DISCLOSURE OF RECEIVED NOTIFICATION

Waregem (Belgium) / Rotterdam (Netherlands)¹, 11 September 2014 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV received a notification on 10 September 2014 from Fidelity Management and Research (FMR LLC) concerning the acquisition or disposal of voting securities. The shareholding of Fidelity Management and Research (FMR LLC) crossed the disclosure threshold of 5% through the acquisition of voting securities.

Based on the denominator of 31,431,360 (total number of voting rights) and the latest notification that Arseus received, Arseus' major shareholders are:

	Number of shares	% of effective voting rights
TIAA-CREF Asset Management LLC	1,635,681	5.22%
BNP Paribas Investment Partners SA	1,609,182	5.13%
Fidelity Management and Research (FMR LLC)	1,573,158	5.01%
AXA S.A.	1,413,820	4.51%
Carmignac Gestion	1,396,407	4.45%

The original notification forms are available at www.arseus.com.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

¹ This press release was sent out by Arseus NV and Arseus BV.

For more information:

Marieke Palstra

Director Investor Relations

+31 88 33 11 213 (Office)

marieke.palstra@arseus.com

Arseus profile

Arseus is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Arseus consists of two divisions: Fagron and HL Technology. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries.

Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals.

The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.